These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38142346)

  • 1. [The development of regulation of medications turn-over in the EU and the USA in 1992-2020. Report I. The formation of normative legal base of pharmaceutical activities in the USA].
    Volskaya EA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Nov; 31(6):1426-1432. PubMed ID: 38142346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chapter 5. The internationalization of the Japanese pharmaceutical industry (1980-2010)].
    Yongue JS
    Yakushigaku Zasshi; 2014; 49(1):77-83. PubMed ID: 25272639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The characteristics of regulation of pharmaceutical market of the Eurasian Economical Union].
    Marseva TG; Voblaia IN; Seifieva EN
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2019 Sep; 27(5):841-846. PubMed ID: 31765534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legal regulation of the production and trade of medical devices and medical equipment in the EU and US: experience for Ukraine.
    Pashkov V; Kotvitska A; Harkusha A
    Wiad Lek; 2017; 70(3 pt 2):614-618. PubMed ID: 28713093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical markets regulation overview of the selected European Union countries.
    Pogorzelczyk K; Synoweć J; Robakowska M; Ślęzak D; Holajn P; Robakowski P; Żuratyński P; Nadolny K
    Wiad Lek; 2018; 71(7):1404-1408. PubMed ID: 30448818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Brazilian pharmaceutical industry and foreign trade: is there evidence of regressive specialization?].
    Mota FB; Cassiolato JE; Gadelha CA
    Cad Saude Publica; 2012 Mar; 28(3):527-36. PubMed ID: 22415185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drugs in the European Union: the health-market complex].
    Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
    Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European drug industry concerned over proposed clinical-trial legislation.
    Rogers A
    Lancet; 1997 Nov; 350(9091):1609. PubMed ID: 11655209
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union.
    Wright JSF; Doukas D
    Health Econ Policy Law; 2021 Jul; 16(3):256-272. PubMed ID: 32583755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is parallel trade in medicines compatible with the single European market?
    Senior I
    Pharmacoeconomics; 1992; 1(Suppl 1):70-6. PubMed ID: 10172047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A regulatory overview of alternatives to animal testing: United States, Europe, and Japan.
    Mayer FL; Whalen EA; Rheins LA
    J Toxicol Cutaneous Ocul Toxicol; 1994; 13(1):3-22. PubMed ID: 11659896
    [No Abstract]   [Full Text] [Related]  

  • 17. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PATENTING OF MEDICINAL PRODUCTS: THE EXPERIENCE OF IMPLEMENTATION OF THE FLEXIBLE PROVISIONS OF THE TRIPS-PLUS AGREEMENT BY FOREIGN COUNTRIES AND THE FUNDAMENTAL PATENT REFORM IN UKRAINE.
    Deshko L
    Georgian Med News; 2018 Sep; (282):161-166. PubMed ID: 30358562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement.
    Gaspar Ernesto LM; Dias Loureiro RM
    PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.